362 related articles for article (PubMed ID: 18222596)
1. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer.
Zelefsky MJ; Yamada Y; Kollmeier MA; Shippy AM; Nedelka MA
Eur Urol; 2008 Jun; 53(6):1172-9. PubMed ID: 18222596
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056
[TBL] [Abstract][Full Text] [Related]
3. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
4. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
Zelefsky MJ; Marion C; Fuks Z; Leibel SA
J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
[TBL] [Abstract][Full Text] [Related]
5. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
Zelefsky MJ; Kattan MW; Fearn P; Fearon BL; Stasi JP; Shippy AM; Scardino PT
Urology; 2007 Aug; 70(2):283-7. PubMed ID: 17826490
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer.
Zelefsky MJ; Ben-Porat L; Chan HM; Fearn PA; Venkatraman ES
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):382-8. PubMed ID: 16965990
[TBL] [Abstract][Full Text] [Related]
8. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
9. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
[TBL] [Abstract][Full Text] [Related]
11. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217
[TBL] [Abstract][Full Text] [Related]
13. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
Zapatero A; Mínguez R; Nieto S; Martín de Vidales C; García-Vicente F
Eur Urol; 2009 Apr; 55(4):902-9. PubMed ID: 18485578
[TBL] [Abstract][Full Text] [Related]
14. [Conformal radiotherapy for patients with clinical stage T1-T3 prostate cancer].
Majewski W; Miszczyk L; Zajusz A
Przegl Lek; 2004; 61(5):503-8. PubMed ID: 15515815
[TBL] [Abstract][Full Text] [Related]
15. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer.
Nguyen PL; Whittington R; Koo S; Schultz D; Cote KB; Loffredo M; Tempany CM; Titelbaum DS; Schnall MD; Renshaw AA; Tomaszewski JE; D'Amico AV
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):400-5. PubMed ID: 15145155
[TBL] [Abstract][Full Text] [Related]
16. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
[TBL] [Abstract][Full Text] [Related]
17. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
18. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
19. Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course.
Bruns F; Franzki C; Wegener G; Karstens JH
Anticancer Res; 2007; 27(4A):1847-51. PubMed ID: 17649783
[TBL] [Abstract][Full Text] [Related]
20. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.
Stock RG; Ho A; Cesaretti JA; Stone NN
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):389-94. PubMed ID: 16965991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
